The discovery of the incretin hormone glucagon like peptide-1 (GLP-1), and its usefulness in the treatment of type 2 diabetes mellitus (T2DM) followed by the finding that dipeptidyl peptidase-4 (DPP-4) inhibition prevents GLP-1 inactivation, led to the discovery of DPP-728. In 1999, studies with DPP-728 established the first proof-of-concept that DPP-4 inhibition improves glycaemic control in patients with T2DM. Further efforts to improve the binding kinetics of DPP-728 resulted in the discovery of vildagliptin (LAF237). In the last 20 years, a plethora of studies conducted by Novartis in collaboration with external investigators has demonstrated the mechanism of action of vildagliptin and its efficacy as monotherapy and as an add-on therapy for patients with T2DM. The studies establish that vildagliptin is a selective DPP-4 inhibitor that blocks GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) inactivation, thereby prolonging their action, resulting in improved glycaemic control. This review aims to discuss the discovery and development of vildagliptin, with an emphasis on mechanism of action and clinical efficacy.
Dipeptidyl peptidase-4 (DPP-4) inhibitors,
glucagon-like peptide-1, glucosedependent
type 2 diabetes mellitus, vildagliptin
James E Foley is an employee
and shareholder of Novartis Pharmaceuticals
Corporation. Bo Ahrén has received speaker
honoraria from Novartis, Merck and Novo Nordisk.
James E Foley,
World Wide Medical Affairs Director, Novartis
Pharmaceuticals Corporation, East Hanover, NJ
07936-1080, US. E: firstname.lastname@example.org
The publication of this article was
supported by Novartis Pharma AG.
Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.
Compliance with Ethics: This article reviews
published human and animal studies; two unpublished
animal studies carried out by and reported with
permission from Sandoz/Novartis; these unpublished
animal studies were carried out according to
standards for the ethical treatment for research
animals existing in New Jersey, US in 1995.
Share this Article
Related Content In Diabetes
Alarming Surge in Early-onset Type 2 Diabetes: A Global Catastrophe on the Horizon
touchREVIEWS in Endocrinology. 2023;19(2):1–2:Online ahead of journal publication
Diabetes mellitus (DM) is a group of metabolic disorders marked by elevated blood glucose. It has many subtypes, including type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes and neonatal diabetes; of these, T1DM and T2DM are the most common. Compared with T1DM, which is characterized by a chronic lack of insulin […]
What is Glycaemic Variability and which Pharmacological Treatment Options are Effective? A Narrative Review
touchREVIEWS in Endocrinology. 2023;19(2):Online ahead of journal publication
The incidence of diabetes has increased in recent years, and advances in technology have allowed for multiple ways to predict the outcomes of patients with diabetes, and have improved quality of life and lowered morbidity and mortality.1 For decades, glycated haemoglobin (HbA1c) has been used as a marker of long-term glycaemic control, and its usefulness as […]
Clinical Profile and Factors Associated with Adverse Outcomes in Coronavirus Disease 2019-associated Mucormycosis: A Single-centre Study
touchREVIEWS in Endocrinology. 2023;19(2):Epub ahead of journal publication DOI: https://doi.org/10.17925/EE.2023.19.2.2
Plan language summary Background The global COVID-19 pandemic resulted in an increased incidence of infection with Black fungus (Mucormycosis). However, the disease characteristics, chances of spread of infection and complications are not well known. Aim of the study We tried to find out the exact reasons behind this rise in the number of cases, whether […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!